OTC Switch Public Policy, Science Issues Workshop Proposed
This article was originally published in The Tan Sheet
Executive Summary
The idea of a public workshop to address certain issues related to the Rx-to-OTC switch process was generally supported by industry representatives and FDAers at a switch summit held by the Consumer Healthcare Products Association in Washington, D.C. July 16.
You may also be interested in...
Healthcare "Rationing" Not Acceptable Reason For Denying Switches - FDAer
The practice of "rationing" a drug, or wanting to keep it out of the hands of the general public, is not an acceptable singular reason for disapproving a switch candidate, FDA Office of Drug Evaluation V Director Robert DeLap, MD/PhD, stated at a switch summit held by the Consumer Healthcare Products Association July 16 in Washington, D.C.
FDA's New OTC Drugs Director Ganley Brings Cardio-Renal Background To Job
Charles Ganley, MD, the new director of FDA's Division of OTC Drugs, brings to the post a background as an agency medical reviewer in the Division of Cardio-Renal Drug Products, where he has worked since 1989. He will report to Office of Drug Evaluation V Director Robert DeLap, MD/PhD.
OTC Denavir Advisory Cmte. Members Uncomfortable With Risk/Benefit Ratio
A joint FDA advisory committee recommended against the Rx-to-OTC switch of SmithKline Beecham's Denavir in a narrow vote, with several members questioning whether the potential risks from broader access to the 1% penciclovir cream for cold sores may outweigh its benefits.